Filing Details
- Accession Number:
- 0001209191-20-048659
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-08-28 17:15:34
- Reporting Period:
- 2020-06-10
- Accepted Time:
- 2020-08-28 17:15:34
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1087294 | Cumberland Pharmaceuticals Inc | CPIX | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1632384 | C Joseph Galante | 2525 West End Avenue Suite 950 Nashville TN 37203 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-06-12 | 225 | $3.37 | 20,992 | No | 4 | P | Direct | |
| Common Stock | Acquisiton | 2020-06-19 | 375 | $3.41 | 21,367 | No | 4 | P | Direct | |
| Common Stock | Acquisiton | 2020-06-26 | 375 | $3.37 | 21,742 | No | 4 | P | Direct | |
| Common Stock | Acquisiton | 2020-07-02 | 300 | $3.34 | 22,042 | No | 4 | P | Direct | |
| Common Stock | Acquisiton | 2020-07-10 | 375 | $3.31 | 22,417 | No | 4 | P | Direct | |
| Common Stock | Acquisiton | 2020-07-17 | 375 | $3.29 | 22,792 | No | 4 | P | Direct | |
| Common Stock | Acquisiton | 2020-07-24 | 375 | $3.33 | 23,167 | No | 4 | P | Direct | |
| Common Stock | Acquisiton | 2020-07-31 | 375 | $3.26 | 23,542 | No | 4 | P | Direct | |
| Common Stock | Acquisiton | 2020-08-07 | 375 | $3.42 | 23,917 | No | 4 | P | Direct | |
| Common Stock | Acquisiton | 2020-08-14 | 375 | $3.44 | 24,292 | No | 4 | P | Direct | |
| Common Stock | Acquisiton | 2020-08-21 | 375 | $3.35 | 24,667 | No | 4 | P | Direct | |
| Common Stock | Acquisiton | 2020-08-26 | 225 | $3.29 | 24,892 | No | 4 | P | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Direct | |
| No | 4 | P | Direct | |
| No | 4 | P | Direct | |
| No | 4 | P | Direct | |
| No | 4 | P | Direct | |
| No | 4 | P | Direct | |
| No | 4 | P | Direct | |
| No | 4 | P | Direct | |
| No | 4 | P | Direct | |
| No | 4 | P | Direct | |
| No | 4 | P | Direct | |
| No | 4 | P | Direct |
Footnotes
- The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2020.
Billionaire Hedge Funds
